{"schema_version":"secwatch.filing_event.v1","accession":"0001428336-22-000031","form_type":"8-K","ticker":"HQY","cik":"0001428336","company_name":"HEALTHEQUITY, INC.","filed_at":"2022-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.623435+00:00","generated_at":"2026-06-21T08:47:18.267848+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HealthEquity Q3 revenue $216.1M (+20% YoY); narrows net loss; guides FY2024 ~$950-970M","bullets":["Revenue $216.1M (+20% YoY); net loss $1.6M vs $5.0M loss; non-GAAP diluted EPS $0.38 vs $0.35.","Adjusted EBITDA $73.4M (+20%); margin 34%; HSAs 7.7M (+23%); total accounts 14.5M (+9%).","FY2023 outlook: revenue $850-860M; Adj EBITDA $261-271M; non-GAAP EPS $1.26-$1.35.","FY2024 initial guidance: revenue ~$950-970M; Adj EBITDA margin ~33-34%; assumes ~2.25% cash yield."],"urls":{"canonical":"https://secwatch.observer/filing/0001428336-22-000031","json":"https://secwatch.observer/filing/0001428336-22-000031.json","markdown":"https://secwatch.observer/filing/0001428336-22-000031.md","text":"https://secwatch.observer/filing/0001428336-22-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1428336/000142833622000031/0001428336-22-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1428336/000142833622000031/hqy-20221206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:47:18.267848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efbbc22a42359a74108a77759c17e619803e6aa6","claim":"HEALTHEQUITY, INC. reported third quarter ended October 31, 2022 results: revenue $216.1 million, net income Net loss of $1.6 million, EPS Net loss per diluted share of $0.02.","evidence_excerpt":"Revenue of $216.1 million, an increase of 20% compared to $180.0 million in Q3 FY22. • Net loss of $1.6 million, compared to $5.0 million in Q3 FY22, with non-GAAP net income of $32.4 million, an increase of 12% compared to $28.9 million in Q3 FY22. • Net loss per diluted share of $0.02, compared to $0.06 in Q3 FY22, with non-GAAP net income per diluted share of $0.38, compared to $0.35 in Q3 FY22.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1428336/000142833622000031/0001428336-22-000031-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended October 31, 2022"},{"label":"Revenue","value":"$216.1 million"},{"label":"Net income","value":"Net loss of $1.6 million"},{"label":"EPS","value":"Net loss per diluted share of $0.02"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}